6326-06-3
6326-06-3
Chemical Structure
AH-7614
- CAS No.: 6326-06-3
- Formula:C20H17NO3S
- Molecular Weight:351.42
IUPAC Name: 4-methyl-N-(9H-xanthen-9-yl)benzenesulfonamide
InChIKey: OZCQEUZTOAAWDK-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(C)C=C1)(NC2C3=C(OC4=C2C=CC=C4)C=CC=C3)=O
Biological Activity: AH-7614 is a potent and selective FFA4 (GPR120) antagonist, with pIC50s of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. AH-7614 has selectivity for FFA4 over FFA1 (pIC50<4.6). AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid and the synthetic FFA4 agonist[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AH-7614 | 99.61% | AH-7614 is a potent and selective FFA4 (GPR120) antagonist, with pIC50s of 7.1, 8.1, and 8.1 for human, mouse, and rat FFA4, respectively. AH-7614 has selectivity for FFA4 over FFA1 (pIC50<4.6). AH-7614 is able to block effects of both the polyunsaturated ω-6 fatty acid linoleic acid and the synthetic FFA4 agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PSB-12062 | 98.05% | PSB-12062 is a potent and selective P2X4 antagonist with an IC50 of 1.38 μM for human P2X4. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
COH34 analog 1 | 98.75% | COH34 analog 1, a metabolite, is an oxidized analog of COH34. COH34 is a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
A 274 | A 274 is an amiodarone analogue that has the activity of inhibiting the binding of T3 to α1- and β1-thyroid hormone receptors in vitro. Its IC50 values for inhibition of α1-T3R and β1-T3R are certain values (depending on the specific experimental results). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TUG-1387 | 98.67 | TUG-1387 is a control compound for the FFA4 antagonists AH-7614 (HY-19996) and TUG-1506 without inhibitroy activity against FFA4. TUG-1387 can be used as a negative control for FFA4 functional assessments. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TH-263 | 99.0% | TH-263, a diaryl sulfonamide derivative, is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
iNOS inhibitor-10 | iNOS inhibitor-10 is an iNOS inhibitor (IC50: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BTS | 99.98% | BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TsDPEN | 99.39% | TsDPEN (Compound 2) is a biochemical reagent. TsDPEN derivatives containing N,N,N imide chiral ligands can be applied to copper catalyzed asymmetric Kinugasa reactions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Xanthenecarboxylic acid (Standard) | ≥98% | Xanthenecarboxylic acid (Standard) is the analytical standard of Xanthenecarboxylic acid. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S,S)-TsDPEN | 99.46% | (S,S)-N-p-Toluenesulfonyl-1,2-diphenylethylenediamine is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sparks SM, et, al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul 15;24(14):3100-3. [Content Brief]
- [2]. Watterson KR, et, al. Probe-Dependent Negative Allosteric Modulators of the Long-Chain Free Fatty Acid Receptor FFA4. Mol Pharmacol. 2017 Jun;91(6):630-641. [Content Brief]
